GLP-1 agonists provide extra geroprotection beyond their effects on obesity. Remember that, clinically, GLP-1 agonists have prevented a variety of age-related diseases (mainly CVD and Kidney Disease) and have been used for a variety of indications in a short period of time.
Two good things about Bryan Johnson: first, I sympathize deeply with the desire to slow aging. Second, whatever one thinks of his methods, he has undeniably brought public attention to our field.
Honored to be included in @TIME list of "Longevity Leaders 2026" Especially happy to see that 6/12 of these are active members of the Academy of Geroscience @aogscience.
What is the paper "Increased genetic protection against Alzheimer's disease in centenarians" about?
I have always wished to make the knowledge I've accumulated over the years accessible to as many as possible. Here's a step towards that. Using all of my papers, interviews, presentations, etc. Delphi has created an avatar of me that anyone can chat with: https://t.co/y9KOCzOwuh